Part A: Upamostat 200 mg
RHB-107-01
Phase 3 small_molecule terminated
Quick answer
Part A: Upamostat 200 mg for Covid19 is a Phase 3 program (small_molecule) at RedHill Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RedHill Biopharma
- Indication
- Covid19
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated